Clinical trial · no report yet · Phase 2
NCT04334941
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
- NCT04334941 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 42 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 34 | |
| YouTube | 7 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Atezolizumab; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Talazoparib
- Arms
- Arm I (atezolizumab) · Active comparator
- Arm II (atezolizumab, talazoparib) · Experimental
- Enrollment
- 103
- Primary outcomes
- Progression free survival
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 20, 2020
- Primary completion
- Nov 30, 2025
- Results posted
- No
- Registry record
- NCT04334941 · updated Jun 5, 2026